公开(公告)号：US20170354617A1

公开(公告)日：2017-12-14

申请号：US15618783

申请日：2017-06-09

Applicant: Research Foundation of the City University of New York

Inventor： Dorra Frikha-Benayed ,  Mitchell B. Schaffler

IPC: A61K31/12 ,  A61K38/17 ,  A61K31/00 ,  G01N33/15

CPC classification number: A61K31/12 ,  A61K31/00 ,  A61K31/5415 ,  A61K38/17 ,  G01N33/15

Abstract: A method for treating or preventing osteoporosis is provided that treats a patient with methylene blue.

公开(公告)号：US20170354603A1

公开(公告)日：2017-12-14

申请号：US15618998

申请日：2017-06-09

Applicant: CHARLESTON LABORATORIES, INC.

Inventor： Paul BOSSE ,  John HIGGINS ,  Bernard SCHACHTEL ,  William KOZAREK

IPC: A61K9/24 ,  A61K31/5415 ,  A61K31/485 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K9/209 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/485 ,  A61K31/5415 ,  A61K2300/00

Abstract: Pharmaceutical compositions are provided, which comprise effective amounts of an opioid analgesic such as oxycodone, and an antiemetic, such as promethazine, to treat a subject for conditions, including for reducing or eliminating an adverse effect associated with the opioid analgesic.

公开(公告)号：US20170348305A1

公开(公告)日：2017-12-07

申请号：US15683646

申请日：2017-08-22

Applicant: LOCL PHARMA, INC.

Inventor： Paul BOSSE ,  John AMELING ,  Bernard SCHACHTEL ,  Ray TAKIGIKU

IPC: A61K31/485 ,  A61K9/20 ,  A61K31/5415 ,  A61K31/522 ,  A61K31/515 ,  A61K31/454 ,  A61K31/437 ,  A61K31/422 ,  A61K31/4196 ,  A61K31/404 ,  A61K31/403 ,  A61K31/24 ,  A61K31/167 ,  A61K31/165 ,  A61K9/48 ,  A61K9/24 ,  A61K45/06 ,  A61K9/16 ,  A61K9/00 ,  A61K47/36

CPC classification number: A61K31/485 ,  A61K9/0024 ,  A61K9/0056 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/165 ,  A61K31/167 ,  A61K31/24 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/437 ,  A61K31/454 ,  A61K31/515 ,  A61K31/522 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/36

Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

公开(公告)号：US20170348304A1

公开(公告)日：2017-12-07

申请号：US15683643

申请日：2017-08-22

Applicant: LOCL PHARMA, INC.

Inventor： Paul BOSSE ,  John AMELING ,  Bernard SCHACHTEL ,  Ray TAKIGIKU

IPC: A61K31/485 ,  A61K9/20 ,  A61K31/5415 ,  A61K31/522 ,  A61K31/515 ,  A61K31/454 ,  A61K31/437 ,  A61K31/422 ,  A61K31/4196 ,  A61K31/404 ,  A61K31/403 ,  A61K31/24 ,  A61K31/167 ,  A61K31/165 ,  A61K9/48 ,  A61K9/24 ,  A61K45/06 ,  A61K9/16 ,  A61K9/00 ,  A61K47/36

CPC classification number: A61K31/485 ,  A61K9/0024 ,  A61K9/0056 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/165 ,  A61K31/167 ,  A61K31/24 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/437 ,  A61K31/454 ,  A61K31/515 ,  A61K31/522 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/36

Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

公开(公告)号：US20170340627A1

公开(公告)日：2017-11-30

申请号：US15679460

申请日：2017-08-17

Applicant: LOCL PHARMA, INC.

Inventor： Paul BOSSE

IPC: A61K31/485 ,  A61K31/167 ,  A61K9/20 ,  A61K9/24 ,  A61K45/06 ,  A61K31/5415

CPC classification number: A61K31/485 ,  A61K9/20 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/167 ,  A61K31/5415 ,  A61K45/06 ,  A61K2300/00

Abstract: Pharmaceutical compositions are provided which comprise effective amounts of an analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.

公开(公告)号：US20170312221A1

公开(公告)日：2017-11-02

申请号：US15523872

申请日：2015-11-04

Applicant: nvenres GmbH

Inventor： Igor GERASHCHENKO ,  Oleksii CHEPLIAKA ,  Andreas TAUSCH

IPC: A61K9/14 ,  C08G77/04 ,  A61K45/06 ,  A61K31/5415 ,  A61K31/167 ,  A61K9/16 ,  C08G77/06 ,  A61K38/48

CPC classification number: A61K9/143 ,  A61K9/0014 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1611 ,  A61K9/1641 ,  A61K31/167 ,  A61K31/5415 ,  A61K38/48 ,  A61K45/06 ,  A61L15/18 ,  A61L15/225 ,  A61L15/26 ,  A61L15/28 ,  A61L15/32 ,  A61L15/44 ,  A61L15/60 ,  A61L26/0004 ,  A61L26/0019 ,  A61L26/0023 ,  A61L26/0038 ,  A61L26/0052 ,  A61L26/0066 ,  A61L26/008 ,  A61L2300/402 ,  A61L2300/404 ,  A61L2300/406 ,  A61L2300/412 ,  A61L2300/45 ,  A61L2300/606 ,  A61L2300/62 ,  A61L2400/04 ,  A61L2420/06 ,  A61L2430/34 ,  C08G77/04 ,  C08G77/06

Abstract: Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

公开(公告)号：US09795568B2

公开(公告)日：2017-10-24

申请号：US13093886

申请日：2011-04-26

Applicant: Martin A. Folger ,  Stefan Lehner ,  Horst Schmitt

Inventor： Martin A. Folger ,  Stefan Lehner ,  Horst Schmitt

IPC: A61K31/5415 ,  B29C43/02 ,  A61K9/20 ,  A61K9/00

CPC classification number: A61K9/2072 ,  A61K9/0056 ,  A61K9/2095 ,  A61K31/5415

Abstract: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

公开(公告)号：US20170296540A1

公开(公告)日：2017-10-19

申请号：US15630328

申请日：2017-06-22

Applicant: Fratagene Therapeutics S.R.L.

Inventor： Roberto Testi ,  Florence Malisan

IPC: A61K31/506 ,  A61K31/5415 ,  A61K31/496 ,  A61K9/00 ,  A61K38/21

CPC classification number: A61K31/506 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/5415 ,  A61K38/217 ,  A61K45/06 ,  A61K2300/00

Abstract: In one aspect, the invention presents a method of treating Friedreich's ataxia (FRDA) by administering a therapeutically effective amount of an Src inhibitor.

公开(公告)号：US09789105B2

公开(公告)日：2017-10-17

申请号：US14930496

申请日：2015-11-02

Applicant: LOCL PHARMA, INC.

Inventor： Paul Bosse ,  John Ameling ,  Bernard Schachtel ,  Ray Takigiku

IPC: A61K9/20 ,  A61K31/485 ,  A61K9/24 ,  A61K31/165 ,  A61K31/167 ,  A61K31/437 ,  A61K31/5415 ,  A61K9/48 ,  A61K31/24 ,  A61K31/515 ,  A61K45/06 ,  A61K31/522 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/454 ,  A61K47/36 ,  A61K9/00 ,  A61K9/16

CPC classification number: A61K31/485 ,  A61K9/0024 ,  A61K9/0056 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/165 ,  A61K31/167 ,  A61K31/24 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/437 ,  A61K31/454 ,  A61K31/515 ,  A61K31/522 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/36

Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

公开(公告)号：US20170266106A1

公开(公告)日：2017-09-21

申请号：US15532425

申请日：2015-12-01

Applicant: Achelios Therapeutics, Inc.

Inventor： Crist J. FRANGAKIS ,  William BAUER ,  Wolfgang LIEDTKE

IPC: A61K9/00 ,  A61K45/06 ,  A61K47/32 ,  A61K31/192

CPC classification number: A61K9/0014 ,  A61K9/06 ,  A61K31/14 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/407 ,  A61K31/415 ,  A61K31/5415 ,  A61K31/616 ,  A61K31/635 ,  A61K45/06 ,  A61K47/32 ,  A61P25/06 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions of an non-steroidal anti-inflammatory drug (NSAIDs) such as, aspirin, diclofenac, ibuprofen, ketoprofen, or naproxen, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The compositions, which can be formulated for topical administration, can provide extended release of the NSAIDs. The compositions of the invention are useful, for example, in the prophylactic treatment or treatment and/or reduction of pain, in the prophylactic treatment or treatment of headaches such as migraine headaches and symptoms of migraine headaches, and in the treatment of temporomandibular disorders (TMD).